A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Clinical trial NCT00136461 · COMPLETED

Trial details

NCT number: NCT00136461
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia Myelodysplastic Syndrome

Start date: 1997-05-01
Primary completion: 2000-08-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.